Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

Tawbi, HA; Schadendorf, D; Lipson, EJ; Ascierto, PA; Matamala, L; Gutierrez, EC; Rutkowski, P; Gogas, HJ; Lao, CD; De Menezes, JJ; Dalle, S; Arance, A; Grob, JJ; Srivastava, S; Abaskharoun, M; Hamilton, M; Keidel, S; Simonsen, KL; Sobiesk, AM; Li, B; Hodi, FS; Long, GV

Tawbi, HA (通讯作者),Univ Texas MD Anderson Canc Ctr, Div Canc Med, 1400 Holcombe Blvd, Houston, TX 77030 USA.

NEW ENGLAND JOURNAL OF MEDICINE, 2022; 386 (1): 24

Abstract

BACKGROUND Lymphocyte-activation gene 3 (LAG-3) and programmed death 1 (PD-1) are distinct inhibitory immune checkpoints that contribute to T-cell exh......

Full Text Link